Research graph
References from Real-world Efficacy of CyberKnife Combined with Systemic Therapy for Primary Liver Cancer: Early Dynamic Changes in Alpha-Fetoprotein as a Core Prognostic Factor. Local targets link to admitted publications; unresolved targets remain external evidence.
Hepatocellular carcinoma
10.1038/s41572-020-00240-3 · 2021 · External reference
Unresolved reference
2024 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
External reference
Spectrum of therapeutic options in hepatocellular carcinoma
10.12965/jer.2550482.241 · 2025 · External reference
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
10.1016/s0140-6736(25)01042-6 · 2025 · External reference
Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma
10.1016/j.ijrobp.2017.09.001 · 2018 · External reference
Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma
10.1016/j.ijrobp.2019.05.066 · 2019 · External reference
Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease
10.1186/s13014-018-1048-4 · 2018 · External reference
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
10.1016/s0140-6736(24)02551-0 · 2025 · External reference
Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study
10.1097/js9.0000000000001819 · 2024 · External reference
Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial
10.1001/jamaoncol.2024.1831 · 2024 · External reference
Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial
10.1001/jamasurg.2024.0506 · 2024 · External reference
Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial
10.1186/s12916-025-04159-y · 2025 · External reference
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial
10.1001/jamaoncol.2024.5403 · 2025 · External reference
Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma
2023 · External reference
Stereotactic body radiation therapy and radiofrequency ablation in patients with hepatocellular carcinoma: not a rival but a partner for the cure
10.21037/hbsn-22-330 · 2022 · External reference
Stereotactic body radiotherapy and other locoregional therapies for hepatocellular carcinoma in patients with cirrhosis: real-world treatment allocation, BCLC-stratified outcomes, and prognostic determinants
2026 · External reference
A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies
10.1016/j.jclinepi.2009.03.001 · 2010 · External reference
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
10.1080/00273171.2011.568786 · 2011 · External reference
Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC
10.1002/jcla.24990 · 2023 · External reference
Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: A meta-analysis
10.1097/md.0000000000016557 · 2019 · External reference
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis
10.1053/j.gastro.2018.01.064 · 2018 · External reference
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab
10.1111/liv.15487 · 2023 · External reference
Efficacy and safety of anlotinib monotherapy for advanced hepatocellular carcinoma and clinical role of α-fetoprotein
10.1038/s41598-025-14759-6 · 2025 · External reference
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
10.1016/j.jhep.2018.03.019 · 2018 · External reference
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
10.1097/hep.0000000000000466 · 2023 · External reference
Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combination therapy
10.3389/fimmu.2024.1508028 · 2024 · External reference
Sensitivity Analysis in Observational Research: Introducing the E-Value
10.7326/m16-2607 · 2017 · External reference
Stereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensity score-matched retrospective analysis
10.3389/fimmu.2026.1644027 · 2026 · External reference
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
10.1055/s-0030-1247132 · 2010 · External reference
mRECIST for HCC: Performance and novel refinements
10.1016/j.jhep.2019.09.026 · 2020 · External reference
Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients
10.1016/j.ijrobp.2005.03.058 · 2005 · External reference
Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers
10.1159/000348669 · 2012 · External reference
Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
10.2147/jhc.s79353 · 2015 · External reference
Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma patients with normal serum alpha-fetoprotein levels
10.1097/jcma.0000000000001305 · 2025 · External reference
LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
10.1016/s0140-6736(24)02575-3 · 2025 · External reference
Stereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensity score-matched retrospective analysis
10.3389/fimmu.2026.1644027 · 2026 · External reference
Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis
2023 · External reference
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
10.1038/s41591-018-0232-2 · 2018 · External reference
Uncertainty method improved on best-worst case analysis in a binary meta-analysis
10.1016/j.jclinepi.2004.09.013 · 2005 · External reference
Survival analysis I: the Kaplan-Meier method
10.1159/000324758 · 2011 · External reference
